Your browser doesn't support javascript.
loading
High in-vivo stability in preclinical and first-in-human experiments with [18F]AlF-RESCA-MIRC213: a 18F-labeled nanobody as PET radiotracer for diagnosis of HER2-positive cancers.
Qin, Xue; Guo, Xiaoyi; Liu, Tianyu; Li, Liqiang; Zhou, Nina; Ma, Xiaopan; Meng, Xiangxi; Liu, Jiayue; Zhu, Hua; Jia, Bing; Yang, Zhi.
Affiliation
  • Qin X; Guizhou University School of Medicine, Guizhou University, Guiyang, 550025, China.
  • Guo X; Key Laboratory of Carcinogenesis and Translational Research, (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100
  • Liu T; Key Laboratory of Carcinogenesis and Translational Research, (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100
  • Li L; Medical Isotopes Research Center and Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing, 100191, China.
  • Zhou N; Key Laboratory of Carcinogenesis and Translational Research, (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100
  • Ma X; Medical Isotopes Research Center and Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing, 100191, China.
  • Meng X; Key Laboratory of Carcinogenesis and Translational Research, (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100
  • Liu J; Guizhou University School of Medicine, Guizhou University, Guiyang, 550025, China.
  • Zhu H; Key Laboratory of Carcinogenesis and Translational Research, (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100
  • Jia B; Key Laboratory of Carcinogenesis and Translational Research, (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100
  • Yang Z; Key Laboratory of Carcinogenesis and Translational Research, (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100
Eur J Nucl Med Mol Imaging ; 50(2): 302-313, 2023 01.
Article in En | MEDLINE | ID: mdl-36129493
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Positron Emission Tomography Computed Tomography Type of study: Diagnostic_studies Limits: Animals / Female / Humans Language: En Journal: Eur J Nucl Med Mol Imaging Journal subject: MEDICINA NUCLEAR Year: 2023 Document type: Article Affiliation country: China Country of publication: Germany
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Positron Emission Tomography Computed Tomography Type of study: Diagnostic_studies Limits: Animals / Female / Humans Language: En Journal: Eur J Nucl Med Mol Imaging Journal subject: MEDICINA NUCLEAR Year: 2023 Document type: Article Affiliation country: China Country of publication: Germany